Yousif Capital Management LLC Sells 249 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Yousif Capital Management LLC reduced its stake in shares of Inari Medical, Inc. (NASDAQ:NARI) by 1.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 19,519 shares of the company’s stock after selling 249 shares during the period. Yousif Capital Management LLC’s holdings in Inari Medical were worth $996,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in NARI. GAMMA Investing LLC raised its position in shares of Inari Medical by 67.2% in the 3rd quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock worth $49,000 after acquiring an additional 473 shares in the last quarter. Everence Capital Management Inc. bought a new position in shares of Inari Medical in the 3rd quarter worth about $315,000. Values First Advisors Inc. bought a new position in shares of Inari Medical in the 3rd quarter worth about $128,000. Asset Management One Co. Ltd. raised its position in shares of Inari Medical by 1.6% in the 3rd quarter. Asset Management One Co. Ltd. now owns 61,354 shares of the company’s stock worth $2,530,000 after acquiring an additional 962 shares in the last quarter. Finally, Financial Enhancement Group LLC bought a new position in shares of Inari Medical in the 3rd quarter worth about $1,155,000. 90.98% of the stock is owned by institutional investors.

Insider Buying and Selling at Inari Medical

In other news, CEO Andrew Hykes sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $55.29, for a total value of $165,870.00. Following the transaction, the chief executive officer now owns 439,310 shares in the company, valued at $24,289,449.90. The trade was a 0.68 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director William Hoffman sold 200,000 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $60.47, for a total value of $12,094,000.00. Following the completion of the transaction, the director now owns 238,987 shares in the company, valued at $14,451,543.89. The trade was a 45.56 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 323,000 shares of company stock worth $18,669,070. Insiders own 10.60% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on NARI shares. Baird R W lowered Inari Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 7th. William Blair restated a “market perform” rating on shares of Inari Medical in a research note on Tuesday, January 7th. Needham & Company LLC restated a “hold” rating on shares of Inari Medical in a research note on Tuesday, October 29th. Oppenheimer assumed coverage on Inari Medical in a research note on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 target price for the company. Finally, BTIG Research restated a “neutral” rating on shares of Inari Medical in a research note on Wednesday, January 8th. Twelve investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $68.00.

Inari Medical Stock Performance

NARI stock opened at $79.93 on Friday. The company has a market capitalization of $4.68 billion, a P/E ratio of -59.21 and a beta of 1.02. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $79.97. The business has a 50-day simple moving average of $69.07 and a two-hundred day simple moving average of $54.31.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.